Table V.
Forward step multivariate modifications of sex in association with recurrence-free survival.
| Model | Modifications | Sex HR | (95% CI) | P-value |
|---|---|---|---|---|
| A | Crude (sex only) | 0.594 | (0.479–0.735) | 0.0001 |
| B | Model A+histology 1 | 0.575 | (0.439–0.755) | 0.0001 |
| C | Model B+age | 0.575 | (0.439–0.755) | 0.0001 |
| D | Model C+Breslow's thickness | 0.632 | (0.471–0.848) | 0.002 |
| E | Model D+Clark's level | 0.648 | (0.479–0.878) | 0.005 |
| F | Model E+mitotic rate | 0.657 | (0.475–0.908) | 0.011 |
| G | Model F+ulceration | 0.676 | (0.484–0.943) | 0.021 |
| H | Model G+site of lesion | 0.676 | (0.484–0.943) | 0.021 |
| I | Model H+metastasis 1 | 0.673 | (0.482–0.939) | 0.020 |
| J | Model I+node 1 | 0.071 | ||
| K | Model I+vertical growth phase | 0.077 | ||
| L | Model J+vertical growth phase | 0.368 | ||
| M | Model I+neurotropism | 0.125 |
Age, <50 vs. ≥50 years; site of lesion, trunk vs. extremities; histology 1, superficial spreading vs. others; Clark's level, I–III vs. IV–V; Breslow's thickness, <2 vs. ≥2 mm; neurotropism, present vs. absent; mitotic rate, ≤3 vs. >3/mm2; ulceration, present vs. absent; vertical growth phase, present vs. absent; TIL, present vs. absent; regression, present vs. absent; precursor lesion, present vs. absent; BRAF, positive vs. negative; node 1, presence of lymph node involvement (yes vs. no); metastasis 1, presence vs. absence; recurrence, yes vs. no; sex, male vs. female. HR, hazard ratio; CI, confidence interval; TIL, tumor-infiltrating lymphocytes.